Nitric Acid

Nitric Acid

SCHEMBL4166394

Cc1ccc(NC(=N)N)cc1Br.O=[N+]([O-])O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
RAB9A P51151 4/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
POLB P06746 1/20 0.40
LMNA P02545 2/20 0.39
MAPK1 P28482 1/20 0.39
PPIA P62937 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitric Acid SCHEMBL1184604 0.86 POLB (0.49) ALDH1A1KDM4ERAB9AMEN1KMT2A
Nitric Acid SCHEMBL27716562 0.86 POLB (0.49) ALDH1A1KDM4ERAB9AMEN1KMT2A
Nitric Acid SCHEMBL6034482 0.82 NPC1 (0.53) ALDH1A1RAB9AMEN1KMT2ANPC1
Nitric Acid SCHEMBL3858285 0.82 KMT2A (0.58) ALDH1A1TDP1RAB9AMEN1KMT2A
SCHEMBL27684440 0.79 KMT2A (0.61) ALDH1A1TDP1RAB9AMEN1KMT2A
Nitric Acid SCHEMBL1833737 0.78 MEN1 (0.46) ALDH1A1RAB9AMEN1KMT2ANPC1
Nitric Acid SCHEMBL9982936 0.78 LMNA (0.49) ALDH1A1KDM4ETDP1RAB9AMEN1
SCHEMBL11834701 0.77 NPC1 (0.43) ALDH1A1KDM4ETDP1RAB9AMEN1
Nitric Acid SCHEMBL3221119 0.77 ALDH1A1 (0.40) ALDH1A1KDM4ERAB9AMEN1KMT2A
Nitric Acid SCHEMBL3250036 0.76 MEN1 (0.48) ALDH1A1KDM4ERAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 ALDH1A1 2743/4885KDM4E 2234/4885TDP1 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.